Project Grant K99HD121925
- The National Institute of Child Health and Human Development awarded Harvard Pilgrim Health Care, Inc., a Project Grant of $763,155 on August 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to evaluate Medicaid coverage policies for rapid genome sequencing in critically ill infants. The research addresses a policy gap: while rapid genome sequencing has demonstrated clinical and cost-effectiveness as a diagnostic tool for genetic disorders in...
- The National Institute of Child Health and Human Development awarded Harvard Pilgrim Health Care, Inc. $703,092 on September 2, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a comprehensive assessment of advanced therapeutic medications in autoimmune disease during pregnancy. The project, titled "Comprehensive Assessment of Medication Risk-Benefit in Autoimmune Disease for Healthy Pregnancies" (CARE-HP), will evaluate safety and...
- The National Institute of Child Health and Human Development awarded The General Hospital Corporation (Massachusetts General Hospital) $443,954 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a four-year mixed-methods assessment of obstetric readiness in low-resource emergency departments. The research addresses the clinical gap created by closures of labor and delivery units that leave 2.3 million women of childbearing age in...
- The National Institute of Child Health and Human Development awarded $436,100 to the University of North Carolina at Charlotte on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and validate non-invasive high-resolution fetal HLA and KIR genotyping protocols using cell-free DNA from maternal blood. The project addresses preeclampsia risk stratification in early pregnancy by developing a high-resolution HLA genotyping protocol...
- The National Institute of Child Health and Human Development awarded Boston Children's Hospital $356,000 on September 1, 2026, under the Child Health and Human Development Extramural Research Projects program (CFDA 93.865) to develop artificial intelligence models that predict neurocognitive outcomes in children with congenital heart disease by integrating clinical, surgical, genomic, and neuroimaging data. The research addresses the gap that nearly half of children and adolescents with...
- This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA program 93.865, "Child Health and Human Development Extramural Research," provides $430,031.00 to evaluate the role of DNA methylation changes in very early preterm birth. The grant, awarded to Harvard T.H. Chan School of Public Health, will support research activities focused on understanding the complex biological mechanisms underlying preterm birth, a critical public...
- The National Institute of Child Health and Human Development awarded Harvard Medical School (operating through the Office of Research Administration of President and Fellows of Harvard College) $464,750 on August 24, 2026, under the Child Health and Human Development Extramural Research Program (CFDA 93.865). The award funds research on genetic variation in genes controlling sperm-egg interactions in reproductively isolated populations of the fish species Astyanax mexicanus. The research...
- The National Institute of Child Health and Human Development awarded Brigham & Women's Hospital Inc. $485,930 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop a colorimetric vaginal insert device for early detection of premature rupture of membranes (PROM) and preterm PROM (PPROM). The device uses a pH-sensitive polymer that reacts to amniotic fluid by releasing a biocompatible dye, producing a visible color change in...
- The National Institute of Child Health and Human Development awarded The Children's Hospital of Philadelphia $795,088 on June 15, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a cluster randomized controlled trial evaluating doula support and healthcare navigation for mothers of preterm infants in neonatal intensive care units. The study, titled Postpartum Care in the NICU (PELICAN), addresses maternal postpartum mortality risk among...
- The National Institute of Child Health and Human Development awarded Boston College $654,483 under Project Grant R01HD117959 on September 15, 2025, through the Child Health and Human Development Extramural Research program (CFDA 93.865). Boston College will analyze Health Care Cost Institute patient claims data to quantify how state reproductive health policies before and after June 2022 affect maternal health outcomes and disparities. The research examines five outcomes: contraceptive use,...
The National Institute of Child Health and Human Development awarded Harvard Pilgrim Health Care, Inc. $126,881 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and evaluate a decision support tool that facilitates informed, shared decision-making regarding prenatal cell-free DNA screening. The project, titled NIPT-AID: Navigating Prenatal Testing—Advancing Informed Decision-Making, addresses gaps between professional guidelines and clinical practice in prenatal counseling. Though current American College of Obstetricians and Gynecologists guidelines recommend cell-free DNA screening as a first-line prenatal option for all pregnant patients, pregnant women report dissatisfaction with their counseling experiences and providers report feeling ill-equipped to discuss the complexities of the screening. The project aims to assess current prescreen counseling practices and the decision-making process from both provider and patient perspectives, identify unmet decisional needs, and develop a decision support tool to facilitate informed choices about prenatal screening. Performance occurs in Boston, Massachusetts, with a period of performance from September 1, 2026, through August 31, 2028. Harvard Pilgrim Health Care, Inc., through its Office of Sponsored Programs division, is the recipient.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $126.9k | 8/28/26 |